Schizophrenia
Conditions
Keywords
Clozapine, hematological monitoring, CHEMPAQ, Granulocytes, WBC
Brief summary
Clozapine remain the drug of choice for treatment resistant schizophrenia and up to 60% of patients not responding to other antipsychotics will respond to clozapine. However, the use of clozapine is restricted due to the risk of agranulocytosis and consequently the need for mandatory hematological monitoring. CHEMPAQ XBC is a point-of-care device that can be used in patients home and analyze WBC and granulocytes by a single capillary blood drop. This study aims to investigate whether this new procedure increases the acceptability of clozapine
Interventions
DEVICEVenous blod sample
Regular venous blood sample withdrawn from the laboratory
DEVICECHEMPAQ
Capillary blood sample analyzed by CHEMPAQ
Sponsors
Aalborg Psychiatric Hospital
University of Aarhus
Study design
Observational model
CASE_CROSSOVER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Treated with clozapine * Compliant with blood monitoring * Willing to give informed consent
Exclusion criteria
* Prior case of agranulocytosis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pain sensation | Monthly for four months | Pain sensation was measured using a visual analog scale (VAS) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The benefits of CHEMPAQ | Monthly for four months | Caregivers and patients were asked about the benefits of using CHEMPAQ for hematological clozapine monitoring. |
Countries
Denmark
Outcome results
None listed